Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2012, Vol. 17 ›› Issue (1): 30-33.

Previous Articles     Next Articles

Analysis on resistance of Acinetobacter Baumannii and the extended spectrum beta-lactamases and carbapenemases

LI Xiao-ning1, LI Juan2, YAO Yong-hong1,3   

  1. 1Department of Laboratory, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001, Anhui, China;
    2Department of Clinical Pharmacy
    3Department of Laboratory, Shexian County People's Hospital, Shexian 245200, Anhui, China
  • Received:2011-09-23 Revised:2011-11-09 Online:2012-01-26 Published:2012-02-16

Abstract: AIM: To analyze drug resistance of Acinetobacter Baumannii and detect the rate of extended spectrum beta-lactamases and carbapenemases which produced by Acinetobacter Baumannii in the hospital.METHODS: The disk diffusion method(K-B)for drug susceptibility testing was used, Clinical and Laboratory Standards Institute(CLSI) was taken for determing ESBL,the carbapenemases was modified by Hodge test.RESULTS: The susceptibility test to antibioties showed the resistance rates were 72.6% to Imipenem and Meropenem, 61.5%-100% to 10 antibioties including Amikacin and Cefotaxime, 34.8% to Cefoperazone/Sulbactam, 54.1% to Levofloxacin. In 135 strains, there were 22 produced ESBL(16.3%), 46 produced carbapenemases(34.1%).CONCLUSION: The drug resistance rate of Acinetobacter Baumannii is high in the hospital, it should be intensified in bacterium detection and drug susceptibility test to guide clinical drug usage more reasonability. Cefoperazone/Sulbactam will be advised as clinical experience of medication. The resistance to beta-lactam in Acinetobacter Baumannii is possibly related to ESBL and carbapenemases.

Key words: Acinetobacter Baumannii, Drug resistance, ESBL, Carbapenemases

CLC Number: